WHO: Keen to see results of trials of Avifavir in covid-19 – Reuters
|Reuters reported that the World Health Organization (WHO) is set to resume its trial of hydroxychloroquine for potential use against the new coronavirus, its head Tedros Adhanom Ghebreyesus said on Wednesday after testing was suspended due to health concerns.
Tedros also told an online media briefing he was "especially worried" about the outbreak in Central and South America, where infections have been spreading rapidly.
Key notes
- World health organization head says continues to respond to other health emergencies while monitoring COVID-19.
- Who's tedros says "especially worried about central and south America".
- World health organization says no reason to modify clinical trial of hydroxychloroquine in COVID-19.
- World health organization says experts advised the continuation of all arms of the solidarity trial, including hydroxychloroquine arm.
- Who chief scientist "no evidence that any drug reducing mortality of patients that have COVID-19".
- Who expert says keen to see results of trials of avifavir in COVID-19.
- Who expert says no indication so far new coronaviris's ability to transmit disease has changed.
- Who expert says hopes trials of hydroxychloroquine will continue until have we definite answer on whether it works.
Market implications
Risk on remains the theme on hopes of a vaccine and while economies open up and start to see V-shaped recoveries in the economic data. More on this here…
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.